RhumbLine Advisers
AURA icon

RhumbLine Advisers’s Aura Biosciences AURA Stock Holding History

RhumbLine Advisers’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$452K Sell
63,657
-1,063
-2% -$7.61K ﹤0.01% 2839
2026
Q1 		$433K Sell
64,720
-314
-0.5% -$1.8K ﹤0.01% 2705
2025
Q4 		$354K Sell
65,034
-4,003
-6% -$23.8K ﹤0.01% 2875
2025
Q3 		$427K Buy
69,037
+3,630
+6% +$23.7K ﹤0.01% 2800
2025
Q2 		$409K Buy
65,407
+1,369
+2% +$8.01K ﹤0.01% 2805
2025
Q1 		$375K Sell
64,038
-9,581
-13% -$72.5K ﹤0.01% 2764
2024
Q4 		$605K Sell
73,619
-269
-0.4% -$2.53K ﹤0.01% 2543
2024
Q3 		$658K Buy
73,888
+10,405
+16% +$89.2K ﹤0.01% 2523
2024
Q2 		$480K Buy
63,483
+18,011
+40% +$132K ﹤0.01% 2709
2024
Q1 		$357K Buy
45,472
+5,589
+14% +$46.3K ﹤0.01% 2882
2023
Q4 		$353K Sell
39,883
-183
-0.5% -$1.55K ﹤0.01% 2871
2023
Q3 		$359K Buy
40,066
+389
+1% +$4.18K ﹤0.01% 2826
2023
Q2 		$490K Buy
39,677
+9,890
+33% +$106K ﹤0.01% 2701
2023
Q1 		$276K Buy
29,787
+7,117
+31% +$73.9K ﹤0.01% 2642
2022
Q4 		$238K Buy
22,670
+331
+1% +$4.21K ﹤0.01% 2743
2022
Q3 		$405K Buy
22,339
+1,626
+8% +$24.6K ﹤0.01% 2593
2022
Q2 		$294K Buy
+20,713
New +$343K ﹤0.01% 2764

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RhumbLine Advisers's AURA Position: Q2 2026 in Review

RhumbLine Advisers reduced its Aura Biosciences (AURA) stake by 1.6% in Q2 2026, selling an estimated $7.61K and leaving 63,657 shares worth $452K. The position accounts for ﹤0.01% of the portfolio, ranked #2839.

RhumbLine Advisers first reported a position in AURA in Q2 2022 and has held it in 17 quarters since. The position peaked at $658K in Q3 2024. 147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • RhumbLine Advisers held 63,657 shares of Aura Biosciences worth $452K as of Q2 2026.
  • RhumbLine Advisers sold 1,063 Aura Biosciences shares in Q2 2026, an estimated $7.61K.
  • Aura Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2839 holding.
  • RhumbLine Advisers first reported a position in Aura Biosciences in Q2 2022 and has held it in 17 quarters since.
  • RhumbLine Advisers's Aura Biosciences position peaked at $658K in Q3 2024.
  • 147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.